Products
Development and supply of safe and effective vaccine for global public healthThe R&D Center of EuBiologics Co., Ltd leverages its in-house developed technology and experiences for vaccine development.
It successfully commercialized the first product, Euvichol¢ç at the end of 2015 and expedites the R&D in order to launch additional
products including vaccines against enteric diseases and prevention of cancer.
Our primary goal is to develop high quality vaccines leveraging R&D capabilities and expertise in biotechnology,
in order to improve the global public health, in particular for children in low and middle income countries.
Below products are under development leveraging our technical expertise and experiences in vaccine development
NAME | Research | Non-Clinical | PhaseⅠ | PhaseⅡ | PhaseⅢ | Approval | Launch |
---|---|---|---|---|---|---|---|
Typhoid conjugate vaccine(EuTCV) |
|||||||
EuBiologics has successfully developed a next-generation typhoid conjugate vaccine that has longer-lived defenses ![]() ![]() ![]() |
|||||||
Pneumococcal conjugate vaccine(EuPCV) |
|||||||
A 15-valent pneumococcal vaccine in which 15 serotypes of pneumococcal polysaccharides ![]() ![]() ![]() |
|||||||
Meningococcal conjugate vaccine(EuMCV) |
|||||||
The first 4-valent meningococcal vaccine produced in Korea, in which 4 serotypes ![]() ![]() ![]() |
|||||||
Cervical cancer vaccine(HPV) |
|||||||
Cervical cancer is caused by certain types of human papillomavirus (HPV). ![]() |
|||||||
* Herpes Zoster Virus (HZV) vaccine |
|||||||
Varicella caused by Varicella Zoster Virus (VZV) remains dormant in a nerve ganglion and becomes active again ![]() |
|||||||
* Respiratory Syncytial Virus (RSV) vaccine |
|||||||
Eubiologics is in the process of developing liposome nanoparticle-based RSV vaccines ![]() |
|||||||
* Alzheimer¡¯s disease vaccine |
|||||||
Alzheimer¡¯s disease is the most common cause of dementia and accounts for 75% of all patients with dementia. ![]() |
|||||||
COVID19 Vaccine |
|||||||
EuBiologics has completed development of a COVID-19 vaccine by producing recombinant antigens ![]() |
* If you¡¯re interested in potential collaboration of our pipeline products, please feel free to contact R&D Center.
* Please click the product name for details.
* Under development in the Joint Venture, EUPOP Life sciences based in USA